Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression
Maintenance intravenous racemic ketamine therapy demonstrated significant, persistent, and broad efficacy for treatment-resistant depression as demonstrated by reductions in Montgomery-Åsberg Depression Rating Scale and Patient-Health Questionnaire-9 total scores and equivocal changes in every item on both rating scales. The magnitude of change in individual items was similar to that of previous randomized trials, with suicidal ideation and depression demonstrating the largest response and appetite disturbance the least.
Authors
- Rachel Landrum (ORCID: https://orcid.org/0000-0001-5947-3695)
- Philip D. Harvey (ORCID: https://orcid.org/0000-0002-9501-9366)
- Michael Banov
- Michelle B. Moore (ORCID: https://orcid.org/0000-0003-4338-1715)
- Amanda Medley Raines (ORCID: https://orcid.org/0000-0002-5717-9289)
- Kevin G. Saulnier (ORCID: https://orcid.org/0000-0003-1280-7138)
Institutions
- Delta Air Lines (United States) (US)
- University of Miami (US)
- Duke University (US)
- Augusta University (US)
- University of Michigan (US)
- VA Center for Clinical Management Research (US)
- Southeast Louisiana Veterans Health Care System (US)
- South Florida Veterans Affairs Foundation for Research and Education (US)
- Louisiana State University Health Sciences Center New Orleans (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1097/jcp.0000000000002060
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00